INSILICO (03696) received a milestone payment of HKD 39 million from Amerilini, and the collaborative project MEN2501 has completed its first patient dosing.

INSILICO (03696) announced that the MEN2501 project licensed to Menarini Group (Menarini) has completed the first patient dosing in Phase I clinical trials. According to the cooperation agreement, INSILICO will receive a milestone payment of approximately 39 million Hong Kong dollars from Menarini. MEN2501 (formerly known as ISM9682) is a highly differentiated small molecule inhibitor targeting the driving protein KIF18A, with preclinical data showing significant inhibitory activity against chromosomal instability cancers. As part of a strategic collaboration aimed at accelerating the development of transformative anti-tumor therapies, INSILICO has licensed the MEN2501 project to Menarini's wholly-owned subsidiary Stemline Therapeutics Inc. for a total collaboration amount of 550 million USD (equivalent to approximately 4.29 billion Hong Kong dollars).